Verily
Precision health technology company, indexed here for its business to business products rather than its consumer app. Lightpath is an AI enabled chronic care management program sold to health plans, employers, and pharmacy benefit managers, using agents to triage and escalate members to a clinical team of physicians, pharmacists, and dietitians, with Lightpath Metabolic covering diabetes, prediabetes, and obesity. Workbench is a research data environment used by the NIH All of Us Research Program, the Michael J. Fox Foundation, and Helix. Sightline is a wastewater based epidemiology program for early infectious disease detection. The free Verily Me consumer application is outside the scope of this record. Formerly an Alphabet subsidiary; became an independent company in March 2026 alongside a $300 million investment round.
Capability Axes
Graded on the indexed B2B products. Lightpath uses agents to triage and escalate members and predictive modeling to identify risk; Workbench is a research data environment; Sightline applies analytics to wastewater signals. Held back from A because Lightpath is a care delivery program wrapping a clinical team of physicians, pharmacists, and dietitians, so the AI is the routing and personalization layer rather than the service being purchased.
Escalation is the explicit design of the product rather than a fallback: agents triage and escalate a member to a licensed clinical team when clinically indicated, and the company states plainly that expert clinicians and coaches remain at the center with AI as a feature. The boundary between what the model does and what a licensed human does is stated more clearly than by most vendors in this index.
Substantial research credibility by association, including Workbench powering the NIH All of Us Research Program with a reported 21,500 researchers. However, outcome evidence for Lightpath itself, the commercial care product, was not retrieved in published form, and the product only reached open enrollment in January 2026. Evidence for the platform is not evidence for the program.
No public pricing. Contact the vendor. Lightpath is subsidized by employers, health plans, and pharmacy benefit managers rather than sold at a published rate; member cost varies by plan.
Lightpath Metabolic is clearly scoped to cardiometabolic conditions including type 1 and type 2 diabetes, prediabetes, and obesity, across tiers of clinical acuity. Held back from A because the company spans care delivery, research infrastructure, and public health surveillance, and the boundaries between those lines are not always clearly drawn in its own materials.
Announced Deployments
Publicly announced health system deployments and partnerships. This is a record of announcements, not an assessment of deployment success or scale.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Employer, health plan, and PBM sponsored programs; separate research and public health contracts | — | — | Vendor Published |
Lightpath is subsidized by employers, health plans, and pharmacy benefit managers rather than sold at a published price, and member out of pocket cost varies by plan. Workbench and Sightline are contracted separately with research and public health organizations.